Massive study of 99,000 people tests Paxlovid's Real-World power against severe COVID

NCT ID NCT07261085

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study looks at health records from about 99,000 adults in Ontario who had COVID-19 and visited a pharmacist. It compares those who got Paxlovid (nirmatrelvir-ritonavir) with those who didn't, to see if the drug lowers the chance of hospitalization, ICU admission, or death within 30 to 60 days. The goal is to understand how well Paxlovid works outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paxlovid (nirmatrelvir-ritonavir)
What this could lead to: If successful, this study could confirm that Paxlovid effectively reduces severe COVID-19 outcomes in a real-world setting, supporting its continued use.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors like patient health differences. It also only looks at data from Ontario, which may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Pfizer New York

New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.